[Pyr1]-Apelin-13

217082-60-5

C69H108N22O16S

H2O : >= 50 mg/mL (32.60 mM)

Others

[Pyr1]-Apelin-13 is a highly potent, selective endogenous apelin receptor (APJ) agonist. In Vitro: [Pyr1]-apelin-13 encapsulation in lipoPEG particles (lipoPEG-PA13) results in sustained and extended drug release under physiological conditions^[1]. In Vivo: [Pyr1]-apelin-13 nanocarriers in a mouse model of pressure-overload induced heart failure demonstrate a sustainable long-term effect of [Pyr1]-apelin-13 in preventing cardiac dysfunction^[1]. [Pyr1] apelin-13 (1, 5 ug) improves locomotor activity and reduces pain symptoms, cavity size and caspase-3 levels in rats. [Pyr1] apelin-13 (1, 5 ug) significantly increases thermal paw withdrawal latency. [Pyr1] apelin-13 in 5 ug dose also produces significant attenuation in paw withdrawal threshold compared to SCI animals from the second week post SCI^[2].